Needham, Massachusetts, United States · Est. 1983
Celldex Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapies and targeted therapies for cancer and other diseases.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
2 drugs in development
By Therapeutic Area
top 3
R&D Momentum
45/100
Pipeline Velocity
15/100
Trial Completion Rate
74/100
Pipeline Concentration
38/100
Pipeline Freshness
87/100
Strategic Signals
Activity
Last 14 days
An Open-Label, Single-Dose Study to Assess the Safety, Pharmacodynamics, and Pharmacokinetics of CDX-622 in Adults With Mild to Moderate Asthma
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study of Barzolvolimab in Participants With Cold Induced Urticaria and Symptomatic Dermographism (EMBARQ-COLDU and SD)
Earlier
Details
Company Overview
—
Mkt Cap
$1.5M
Revenue
$28.4M
Cash
Therapeutic Focus
Recent SEC Filings
Celldex Therapeutics, Inc. (CLDX) (CIK 0000744218)
Pipeline
Regulatory
Celldex Therapeutics, Inc. (CLDX) (CIK 0000744218)
Accession: 000-15006
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)